Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here